NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Forecast, Price & News $45.36 -0.56 (-1.22%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$44.95▼$45.9450-Day Range$41.19▼$52.2552-Week Range$25.97▼$58.38Volume684,317 shsAverage Volume678,985 shsMarket Capitalization$2.52 billionP/E RatioN/ADividend YieldN/APrice Target$65.86 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Akero Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.2% Upside$65.86 Price TargetShort InterestBearish11.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.43Based on 16 Articles This WeekInsider TradingAcquiring Shares$3.41 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.70) to ($3.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector548th out of 961 stocksPharmaceutical Preparations Industry250th out of 454 stocks 3.5 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.86, Akero Therapeutics has a forecasted upside of 45.2% from its current price of $45.36.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.38% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 2.5 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Akero Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have bought 28.65% more of their company's stock than they have sold. Specifically, they have bought $3,413,700.00 in company stock and sold $2,653,443.00 in company stock.Percentage Held by InsidersOnly 9.69% of the stock of Akero Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($2.70) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akero Therapeutics (NASDAQ:AKRO) StockAkero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesSeptember 25, 2023 | markets.businessinsider.comLifeSci Capital Remains a Buy on Akero Therapeutics (AKRO)September 25, 2023 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives $65.86 Average Price Target from AnalystsSeptember 25, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.September 23, 2023 | americanbankingnews.comAnalysts Set Expectations for Akero Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:AKRO)September 20, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Akero TherapeuticsSeptember 20, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Receives New Coverage from Analysts at Cantor FitzgeraldSeptember 19, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Akero Therapeutics (AKRO) with Overweight RecommendationSeptember 19, 2023 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest UpdateSeptember 25, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.September 19, 2023 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 25,000 SharesSeptember 15, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Price Target Increased to $60.00 by Analysts at Evercore ISISeptember 14, 2023 | msn.comEvercore ISI Group Maintains Akero Therapeutics (AKRO) Outperform RecommendationSeptember 14, 2023 | finance.yahoo.comMadrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDASeptember 6, 2023 | msn.comJP Morgan Maintains Akero Therapeutics (AKRO) Overweight RecommendationAugust 31, 2023 | finance.yahoo.comAkero Therapeutics to Present at Upcoming Healthcare Conferences in SeptemberAugust 28, 2023 | baystreet.caAkero Gains on Buy Rating, Test ResultsAugust 28, 2023 | finance.yahoo.comAkero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023August 24, 2023 | seekingalpha.comAkero Therapeutics: An AssessmentAugust 12, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)August 11, 2023 | finance.yahoo.comAkero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 11, 2023 | finance.yahoo.comInfinity Pharma (INFI) Stock Up on Advancing Cancer StudyJuly 10, 2023 | finance.yahoo.comAxsome (AXSM) Doses First Patient in Late-Stage ADHD StudyJuly 10, 2023 | finance.yahoo.comSotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid DemandJuly 10, 2023 | finance.yahoo.comViking Therapeutics (VKTX) Surges 64% Year to Date: Here's WhyJuly 3, 2023 | finance.yahoo.comAlnylam (ALNY) Announces FDA Committee Onpattro sNDA Review DateJuly 3, 2023 | finance.yahoo.comBaudax Bio (BXRX) Up 125% on Acquiring TeraImmuneJune 29, 2023 | finance.yahoo.comAxsome (AXSM) Down on Public Offering of Common StockSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Company Calendar Last Earnings8/11/2023Today9/25/2023Next Earnings (Estimated)11/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.86 High Stock Price Forecast$83.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+45.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.01% Return on Assets-26.42% Debt Debt-to-Equity Ratio0.04 Current Ratio29.77 Quick Ratio29.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book6.50Miscellaneous Outstanding Shares55,600,000Free Float50,214,000Market Cap$2.52 billion OptionableNot Optionable Beta-0.94 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 56)Ph.D., Pres, CEO & Director Comp: $1.22MDr. Jonathan M. Young J.D. (Age 53)Ph.D., Co-Founder, Exec. VP, COO & Sec. Comp: $763.3kDr. Timothy Rolph (Age 69)Co-Founder & Chief Scientific Officer Comp: $819.4kMr. William R. White J.D. (Age 50)Exec. VP, CFO, Treasurer & Head of Corp. Devel. Comp: $768.4kMs. Catriona Yale (Age 51)Exec. VP & Chief Devel. Officer Comp: $754.8kMr. Patrick Lamy (Age 50)Sr. VP of Commercial Strategy Mr. John J. Schembri (Age 61)VP of Fin. & Controller More ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRIndiviorNASDAQ:INDVProthenaNASDAQ:PRTAHUTCHMEDNASDAQ:HCMBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsAndrew ChengSold 25,000 sharesTotal: $1.24 M ($49.77/share)Catriona YaleSold 5,745 sharesTotal: $287,192.55 ($49.99/share)Perceptive Advisors LLCBought 1,417,150 shares on 8/24/2023Ownership: 3.490%Wolverine Trading LLCBought 5,600 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 14,217 shares on 8/21/2023Ownership: 0.097%View All Insider TransactionsView All Institutional Transactions AKRO Stock - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price forecast for 2023? 8 Wall Street analysts have issued 12 month price objectives for Akero Therapeutics' stock. Their AKRO share price forecasts range from $58.00 to $83.00. On average, they anticipate the company's share price to reach $65.86 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2023? Akero Therapeutics' stock was trading at $54.80 on January 1st, 2023. Since then, AKRO stock has decreased by 17.2% and is now trading at $45.36. View the best growth stocks for 2023 here. Are investors shorting Akero Therapeutics? Akero Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,330,000 shares, an increase of 8.0% from the August 15th total of 5,860,000 shares. Based on an average daily trading volume, of 678,200 shares, the short-interest ratio is presently 9.3 days. View Akero Therapeutics' Short Interest. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Friday, August, 11th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.01. What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? (AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. What is Akero Therapeutics' stock symbol? Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO." Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.63%), State Street Corp (4.47%), Perceptive Advisors LLC (3.49%), General Atlantic L.P. (3.56%), Boxer Capital LLC (3.35%) and Commodore Capital LP (3.34%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akero Therapeutics' stock price today? One share of AKRO stock can currently be purchased for approximately $45.36. How much money does Akero Therapeutics make? Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $2.52 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. How can I contact Akero Therapeutics? Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com. This page (NASDAQ:AKRO) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.